Scarica l'app Stockscreener
10.93
1.09%
-0.12
Dopo l'orario di chiusura:
10.80
-0.13
-1.19%
Precedente Chiudi:
$11.05
Aprire:
$11.09
Volume 24 ore:
850.53K
Relative Volume:
0.49
Capitalizzazione di mercato:
$1.40B
Reddito:
-
Utile/perdita netta:
$-29.07M
Rapporto P/E:
-37.69
EPS:
-0.29
Flusso di cassa netto:
$-31.85M
1 W Prestazione:
-0.09%
1M Prestazione:
-3.19%
6M Prestazione:
+49.11%
1 anno Prestazione:
+169.88%
Intervallo 1D:
$10.79
$11.30
Intervallo di 1 settimana:
$10.41
$11.81
Portata 52W:
$3.9304
$14.39
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Nome
Trevi Therapeutics Inc
Settore
Industria
Telefono
203-304-2499
Indirizzo
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
10.93 | 1.42B | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-13 | Iniziato | Leerink Partners | Outperform |
| 2025-08-21 | Iniziato | Morgan Stanley | Overweight |
| 2025-07-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-05-28 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-10 | Reiterato | Needham | Buy |
| 2025-03-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-30 | Iniziato | Raymond James | Outperform |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-04-12 | Iniziato | B. Riley Securities | Buy |
| 2022-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | BMO Capital Markets | Outperform |
| 2019-06-03 | Iniziato | Needham | Buy |
| 2019-06-03 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | Stifel | Buy |
Mostra tutto
Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie
Fed Watch: Can Trevi Therapeutics Inc continue delivering strong returns2025 Market Trends & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
New Haven biotech Trevi Therapeutics builds billion-dollar valuation around lone late-stage cough drug - Hartford Business Journal
Analysts Conflicted on These Healthcare Names: Encompass Health (EHC), Hims & Hers Health (HIMS) and Trevi Therapeutics (TRVI) - The Globe and Mail
Aug Outlook: How does Trevi Therapeutics Inc compare to its peersQuarterly Earnings Summary & AI Driven Price Predictions - baoquankhu1.vn
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Brokerages - MarketBeat
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know - MSN
Tejara Capital Ltd Trims Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Advances Toward Treatment for Debilitating Cough - AD HOC NEWS
Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Strong Buy Ratings and Nearly 100% Upside Potential - DirectorsTalk Interviews
Will Trevi Therapeutics Inc. benefit from rate cutsJuly 2025 Review & Technical Confirmation Trade Alerts - mfd.ru
Can Trevi Therapeutics Inc. continue delivering strong returnsWeekly Profit Analysis & High Accuracy Trade Alerts - mfd.ru
ETF Watch: Is Nabors Industries Ltd showing insider buyingTrade Exit Summary & Growth Oriented Trading Recommendations - baoquankhu1.vn
Weekly Recap: Does Trevi Therapeutics Inc offer margin of safetyShort Setup & Verified High Yield Trade Plans - baoquankhu1.vn
Coulter Partners Recruits CFO for Trevi Therapeutics - Hunt Scanlon Media
Is Trevi Therapeutics Inc a momentum stockEarnings Performance Report & Detailed Earnings Play Strategies - baoquankhu1.vn
Trevi Therapeutics Advances Toward Key Regulatory Review Following Clinical Validation - AD HOC NEWS
Trevi Therapeutics (NASDAQ:TRVI) Shares Down 6.5%Here's Why - MarketBeat
Trevi Therapeutics (TRVI) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Trevi Therapeutics Reports Positive Results on Treatment for Chronic Cough; Shares Rise - marketscreener.com
Trevi Therapeutics (TRVI) Publishes Positive Phase 2b Trial Resu - GuruFocus
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA) - PR Newswire
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Artiva Biotherapeutics, Inc. (ARTV) and Oncolytics Biotech (ONCY) - The Globe and Mail
Aug Action: Is Trevi Therapeutics Inc a top pick in the sectorJuly 2025 PreEarnings & Low Risk High Win Rate Picks - baoquankhu1.vn
Is Trevi Therapeutics Inc. stock technically oversoldBear Alert & Accurate Buy Signal Alerts - bollywoodhelpline.com
New trial links cough counts to how IPF patients feel on oral treatment - Stock Titan
Will Trevi Therapeutics Inc outperform tech stocksPortfolio Gains Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Trevi Therapeutics’ Earnings Call Highlights Promising Outlook - MSN
Coulter Partners successfully led a search assignment for Trevi Therapeutics, Inc. (Nasdaq: TRVI) and is pleased to announce the placement of David Hastings as Chief Financial Officer (CFO) - Hunt Scanlon Media
Trevi Therapeutics (TRVI) targets next phase of growth with leadership change - MSN
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of “Buy” by Brokerages - Defense World
Trevi Therapeutics (TRVI) Valuation Check After FDA End Of Phase 2 Update And Renewed Analyst Optimism - Yahoo Finance
Is Trevi Therapeutics (TRVI) Building a Multi-Indication Moat With Its Nalbuphine ER Cough Strategy? - Yahoo Finance
Peregrine Capital Management LLC Invests $5.68 Million in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Given “Buy” Rating at HC Wainwright - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from HC Wainwright - MarketBeat
Trevi Therapeutics (TRVI) Receives Reiterated 'Buy' Rating from HC Wainwright & Co. | TRVI Stock News - GuruFocus
Trevi Therapeutics’ (TRVI) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference - Sahm
Published on: 2026-01-09 09:26:05 - Улправда
Will Trevi Therapeutics Inc. stock maintain momentum in 2025Quarterly Growth Report & Long Hold Capital Preservation Plans - Улправда
Will Trevi Therapeutics Inc. stock split again soonJuly 2025 Macro Moves & Community Consensus Trade Alerts - Улправда
Growth Value: Can Trevi Therapeutics Inc. stock maintain growth trajectoryProfit Target & Verified Entry Point Signals - ulpravda.ru
Can Trevi Therapeutics Inc. stock maintain growth trajectoryJuly 2025 Intraday Action & Reliable Breakout Stock Forecasts - Улправда
Sentiment Recap: Can TPIC stock surprise with earnings upsideJuly 2025 Earnings & Comprehensive Market Scan Insights - moha.gov.vn
Aug Shorts: Can Trevi Therapeutics Inc stock maintain growth trajectory2025 Winners & Losers & Reliable Momentum Entry Alerts - Bộ Nội Vụ
What dividend safety score for Trevi Therapeutics Inc. stockPortfolio Profit Report & Weekly High Potential Alerts - Улправда
Trevi Therapeutics Outlines Key Development Milestones for Lead Drug Candidate - AD HOC NEWS
Is Trevi Therapeutics Inc. stock trading at a premium valuation2025 Sector Review & Capital Efficiency Focused Strategies - Улправда
Trevi Therapeutics schedules FDA meeting for chronic cough program By Investing.com - Investing.com India
Will Trevi Therapeutics Inc. stock gain from strong economy2025 Institutional Moves & Technical Buy Zone Confirmation - Улправда
Trevi Therapeutics Inc Azioni (TRVI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):